Larvol Delta - MAESTRA-3-Phase-3-Study-of-INCB123667-Plus-Bevacizumab-Versus-Bevacizumab-Alone-as-FirstLine-Maintenance-Therapy-in-Ovarian-Cancer-Overexpressing-Cyclin-E1

Avastin (bevacizumab) - Roche

INCB123667 - Incyte

http://clinicaltrials.gov/ct2/show/NCT07797283

Sep 2, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next